BioSenic SA

Equities

BIOS

BE0974280126

Pharmaceuticals

Real-time Euronext Bruxelles 12:23:12 2024-03-28 pm EDT 5-day change 1st Jan Change
0.022 EUR 0.00% Intraday chart for BioSenic SA -1.79% -64.05%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Biosenic S.A. Releases Details of Optimized Administration Approach Ahead of Planned Phase 3 Trial of OATO for Chronic Graft-Versus-Host Disease CI
BioSenic Raises Capital to Fund US FDA Application for Oral Arsenic Trioxide MT
BioSenic S.A. announced that it has received ?0.5 million in funding from Société Boursier.com SA, Gestys Sprl, Friedland Gestion CI
BioSenic Unit Wins Canadian Patent for Therapeutic Platform MT
BioSenic S.A. Patent Granted in Canada for Broader Protection of ATO Therapeutic Platform CI
BioSenic Presents New Phase 3 Data on JTA-004 to Treat Severe Osteoarthritis Pain at the 2024 OARSI World Congress CI
BioSenic Files US Patent for Osteoarthritis Therapy MT
BioSenic Files for Additional Patent Protection Following New Clinical Evidence of Efficacy for JTA-004 in OA CI
Biosenic: partnership with Phebra PTY evolves CF
BioSenic Signs Binding Term Sheet with Phebra for Oral Formulation Development of cGvHD Treatment MT
BioSenic Reaches Agreement on A Binding Term Sheet with Phebra PTY Ltd. with Respect to the Development of the First Oral Formulation of Arsenic Troxide for cGvHD Treatment CI
BioSenic Names Chief Scientific Officer as COO MT
Biosenic S.A. and Its Subsidiary Medsenic SAS Announces the Promotion of Carole Nicco to Chief Operating Officer CI
BioSenic S.A. announced that it expects to receive ?1.2 million in funding from Abo-Security S.R.L. CI
BioSenic S.A. announced that it expects to receive $9.6 million in funding CI
BioSenic S.A. Performs Further Analysis of Its Phase 2 Clinical Trial Data, Leading to an Optimal Administration Scheme for Its Next Late-Stage Trial of Arsenic Trioxide in cGvHD CI
BioSenic Publishes New Evidence of Beneficial Effects of Arsenic Treatment Supporting Clinical Trial for Systemic Sclerosis CI
BioSenic Strikes Debt Restructuring Deal with Creditors; Stock Gains MT
BioSenic Secures Patent in China for Arsenic Trioxide Platform MT
BioSenic Commences Debt Renegotiation, Secures Standstill Agreement MT
Global markets live: Airbus, Intel, Meta Platforms, Berkshire Hathaway... Our Logo
BioSenic Halts Mid-stage Bone Repair Study to Focus on Autoimmune Disease Asset MT
BioSenic S.A. Puts Phase IIb Allob Trial on Hold CI
BioSenic to Advance Viscosupplement Plans for Knee Osteoarthritis MT
BioSenic Secures New European Patent for Therapeutic Use of Arsenic Trioxide, Copper Salts MT
Chart BioSenic SA
More charts
BioSenic SA is a leading biotech company specializing in the development of clinical assets issued from the allogeneic cell therapy platform ALLOB and from the Arsenic TriOxide (ATO) platform. Key target indications for the platforms include Graft versus Host Disease (GvHD), Systemic lupus erythematosus (SLE), Systemic Sclerosis (SSc) and high-risk tibial fractures. Following the merger in October 2022, BioSenic SA combines the strategic positionings and strengths of Medsenic and Bone Therapeutics. The merger also enables Biosenic SA to add to its innovative cell therapy platform and strong IP for tissue repair protection with an entirely new arsenal of various anti-inflammatory and anti-autoimmune formulations using the immunomodulatory properties of ATO/OATO.
More about the company
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
2
Last Close Price
0.022 EUR
Average target price
0.1 EUR
Spread / Average Target
+354.55%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock BioSenic SA - Euronext Bruxelles
  4. News BioSenic SA
  5. Bone Therapeutics Raises $4 Million To Advance Lead Orthopedic Asset